Nuformix files first cannabinoid cocrystal patent
Progress at Nuformix, the pharma development company which uses co-crystal technology to unlock the therapeutic potential of approved small molecule drugs, continues apace with the arrival of a lung fibrosis specialist to the advisory board and a first patent filing under the agreement with Ebers Tech of Canada.
The appointment of Dr Muhunthan Thillai to Nuformix’s scientific advisory board reflects progress made with Nuformix’s NXP002 programme as a treatment for idiopathic lung fibrosis (IPF) as it finalises its clinical development plans. Dr Thillai is the lead clinician for the Cambridge Interstitial Lung Disease Unit, where he is also a consultant.
Nuformix managing director Dan Gooding said: “I’m delighted to announce Dr Thillai’s appointment as he is a unique individual. Muhunthan has a complete understanding of IPF patients, from those newly diagnosed to those receiving lung transplants at end stage and runs the UK’s second largest IPF patient clinic at Royal Papworth.